Touch screens as a tool in patient care in the IBD outpatient clinic

Abstract

It is feasible to introduce touch screens in the outpatient clinic and to have patients record their symptoms before the consultation. However, the study may not be representative for elderly patients.

Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review

“…Twenty articles were excluded for the following reasons: the reported instrument was not patient-reported (10); the reported instrument did not assess disease activity (6); or the article did not provide measurement properties of the PROM (4). Finally, 17 articles were included covering the following instruments: self-administered SCCAI, 9 6-point Mayo score, 10,11 patient-assessment of disease activity, 11 Manitoba Inflammatory Bowel Disease Index (MIBDI), 12 survey-index CDAI, 13 patient-based PUCAI, 14 patients' global assessment, 15 patient-SCCAI, 16 patient-HBI, 17 Numeric Rating Scale (NRS), 18 mobile health index (mHI), 19 patient-reported outcome derived from the Mayo score (PRO2), 20 patient-reported outcome derived from the CDAI (PRO3), 21 simple 0-10 numerical score (IBD-10), 22 patient-reported HBI, 23 patient-reported SCCAI, 23 digital self-administered SCCAI, 24,25 and digital self-administered HBI. 25…”

“…Three studies included patients with CD, 13,17,21 a total of 8 included patients with UC, [9][10][11][14][15][16]20,24 and 6 included both CD and patients with UC. 12,18,19,22,23,25 . Most studies included only adult patients, whereas 2 included children in their studies.…”

“…Both studies showed good agreement between the HBI and SCCAI filled out on paper and via a web tool. 24,25 Five studies used subcomponents of a conventional clinical index to develop a new PROM. Three of these used the 2 patient-reported items from the Mayo score (ie, stool frequency and rectal bleeding).…”

Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999–2014

“…Patients were identified through GASTROBIO, a web-based registry of IBD patients established both for research purposes and to optimize clinical management. 25 All patients with a diagnosis of UC or CD who had been treated with IFX as their first biologic agent during 1999-2014 were included. The initial dosing of IFX was 5 mg/kg at weeks 0, 2, and 6, and then every 8 weeks.…”

“…The region has a tradition for collecting data on all IBD patients dating back to 1978 26 and has since the introduction of IFX recorded all patient characteristics and treatments in the GASTROBIO database. 25 GASTROBIO delivers data to the Danish National Registry for Biological Therapy in Inflammatory Bowel Disease (BIO-IBD). Entering data into BIO-IBD is mandatory in all departments in Denmark prescribing biological therapy.…”